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INTRODUCTION 
 Patritumab is a fully human anti–epidermal growth factor receptor 3 (HER3) monoclonal 
antibody that binds to the extracellular domain of HER31–3  
– HER3 signaling is associated with high expression of heregulin (HRG)4, which has been 
shown to be important for tumour growth and proliferation 
– When combined with epidermal growth factor receptor (EGFR) inhibitors, patritumab 
enhances in vitro anti-tumour activity and prevents HER3 activation following anti-EGFR 
treatment1,3,5 
 Evidence is growing that HRG presence affects disease progression and survival 
– In a phase 2 study in non–small-cell lung cancer, treatment with patritumab + erlotinib 
increased progression-free survival (PFS) in patients with high HRG mRNA expression 
(HRG-high)6,7 
 A phase 1b study in patients with SCCHN (clinicaltrials.gov identifier: NCT02350712) 
demonstrated safety, tolerability, and tumour response of patritumab + cetuximab + cisplatin or 
carboplatin and informed the patritumab dose regimen in the phase 2 study 
– As of January, 2016, the tumour response rate (complete response [CR] + partial 
response [PR]) for all 15 patients was 47%: CR: n=3 (20%); PR: n=4 (27%); stable disease 
(SD): n=8 (53%), and progressive disease (PD): n=0 (0%) (disease control rate = 100%) 
 The best (minimum) percent change in the sum of diameters from baseline in 
target lesions for each patient is illustrated in Figure 19 
– The recommended phase 2 dose of patritumab is 18-mg/kg loading dose, followed by a 
9-mg/kg maintenance dose every 3 weeks, maintaining patritumab trough 
concentrations above the inhibitory concentration 90% derived from preclinical data8 
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Figure 1. Best (minimum) percent change in sum of diameters from baseline in target lesions (safety 
analysis population)9  
 
 
PURPOSE 
 A phase 2 study was designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of 
first-line patritumab + cetuximab + platinum vs. placebo + cetuximab + platinum in heregulin 
HRG-expressing recurrent and/or metastatic SCCHN (NCT02633800)  
 The design of the phase 2 study is presented 
 
STUDY DESIGN 
Overall Design 
 This is a multicentre, randomised, placebo-controlled, double-blind phase 2 study in Europe to 
evaluate PFS and safety in recurrent/metastatic first-line SCCHN in subjects treated with either 
patritumab or placebo + cetuximab + platinum-based therapy (Figure 2) 
 Approximately 105 subjects from ~35 sites in Europe will be stratified 2:1 by HRG status (70 
HRG-high; 35 with low HRG expression [HRG-low]), and then randomized 1:1 to the patritumab 
or placebo arm 
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Figure 2. Phase 2 study design 
 
 
HRG, heregulin; PFS, progression-free survival. 
 
 
 
 
Treatment 
 Study treatment regimens, shown in Figure 3, include: 
– Intravenous patritumab (18-mg/kg loading dose; 9-mg/kg maintenance dose every 3 
weeks [q3w]) or placebo 
– Cetuximab (400-mg/m2 loading dose; 250-mg/m2 maintenance dose weekly) 
– Up to 6 cycles of cisplatin (100 mg/m2 q3w) or carboplatin (area under the curve of 5) 
 Patients demonstrating CR, PR, or SD will be treated with patritumab or placebo + cetuximab + 
≤6 cycles platinum for the study duration (until all patients have died or ≥13 months 
postrandomisation of last patient) 
– Those benefiting may continue therapy with patritumab + cetuximab (platinum-based 
therapy for ≤6 cycles) uninterrupted in an open-label extension phase until progressive 
disease, toxicity, or withdrawal 
 Reasons for discontinuation include: PD per Response Evaluation Criteria In Solid Tumors 
(RECIST) 1.1 or clinician’s assessment, adverse event (AE), death, withdrawal of consent, 
significant protocol violation, or study termination by the study 
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Figure 3. Order and timing of study treatment [Authors, we will omit figure if space is needed] 
  
 
AUC, area under the curve; hr, hour; IV, intravenous; wk, week. 
 
 
Study End Points 
 Primary efficacy end point: PFS 
 Secondary end points 
– Efficacy: overall survival (OS); overall response rate (ORR [CR + PR]) 
– PK: area under the curve from 0-t and maximum concentration for serum patritumab, 
cetuximab, and platinum 
– Safety: treatment-emergent AEs, grade ≥3 AEs; myocardial infarction status; 
electrocardiograms, vital signs, physical exams, and including human anti-human 
antibody incidence 
 
Key Inclusion Criteria 
 Age ≥18 years 
 Histologically confirmed recurrent disease or metastatic SCCHN 
 Documented HRG expression (per archived or fresh biopsy)  
 Measurable disease per RECIST criteria 
 Human papilloma virus (HPV) status or p16 (HPV surrogate) 
 Eastern Cooperative Oncology Group performance status 0 or 1 
 Adequate haematological, renal, and hepatic function 
 Prothrombin time or partial thromboplastin time ≤1.5 x upper limit of normal 
Harrington Phase 2 SCCHN poster  ASCO 2016; 3-7 June 
 
5 
 
 
Key Exclusion Criteria 
 Left ventricular ejection fraction <50% 
 Prior EGFR targeted regimen or anti-HER3 therapy 
 Prior treatment with chemotherapy for recurrent/metastatic disease; anti-cancer therapy 
between biopsy and submission of sample; platinum-containing drug therapy with radiotherapy 
<6 months prior to the study; or therapeutic or palliative radiation therapy or major surgery ≤4 
weeks prior to the study 
 Squamous cell tumours of the nasopharynx 
 Known history of brain metastases or active brain metastases 
 History of other malignancies, except adequately treated non-melanoma skin cancer, curatively 
treated in-situ disease, or other solid tumours curatively treated with no evidence of disease for 
≥2 years 
 Presence of hemorrhagic tumors (for patients receving carboplatin) 
 Uncontrolled hypertension, clinically significant electrocardiograph findings, myocardial 
infarction ≤1 year prior to enrolment; symptomatic congestive heart failure, unstable angina, or 
arrhythmia requiring medication 
 
Assessments 
 A schedule of key study assessments is shown in Table 1 
 At tissue screening (prior to study screen), patients provided informed consent for tumour 
tissue and were screened for serious AEs related to the biopsy procedure 
 At study screen, criteria for study inclusion (including HRG level HPV) will be assessed 
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Table 1. Schedule of Assessments 
Assessment 
Screening 
(≤14 days) 
Treatment Cycle 
Every 6 
Weeks 
End of Study 
21 Days 
After Last 
Dose 
40 Days 
After Last 
Dose 
ECOG X 
 Cycle 1: Day 1 predose; Day 8; Day 15 
 Cycles 2, 3, and ≥4: Day 1 
 X  
ECHO or MUGA X  Cycle 3 and every 3rd subsequent cycle: Day 1a  X  
ECG (12-lead) X   X  
AEs X 
 Cycle 1: Day 1 predose and EOI; Days 8 and 15 
 Cycles 2, 3, and ≥4: Day 1b 
 X Xc 
PK (all patients)  
 Cycle 1: Day 1 predosed and EOI 
 Cycles 2 and 3: Day 1 
 X  
PK (subgroup; n=30)  
 Cycle 1: Day 1 predosed and EOI; Days 2, 3, 8, and 15 
 Cycles 2 and 3: Day 1e 
   
HAHA  
 Cycle 1: Day 1 predosed 
 Cycles 2 and 3: Day 1 
 X  
Tumour responsef X  Xg X  
Survival follow-up     Xh 
Biomarkers  
 Cycle 1: Day 1 predosei 
 Cycles 2 and 3: Day 1 
 End of Cycle 6 and every 4 cycles 
 X X 
aAdditional tests may be performed at the discretion of the investigator. The same test (echocardiogram [ECHO] or multigated 
acquisition scan [MUGA]) must be used for a subject throughout the study; 
bCan be collected on Days 8 and 15 in all subsequent cycles at the discretion of the Investigator; 
cForty days after last dose of study drug, adverse events (AEs) will be assessed via a phone call to the patient; 
dAssessment can be performed ≤3 days prior to visit; 
eCorresponds to Cycle 1, Day 21 (504 hours); 
fPer Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; 
gEvery 6 weeks to Week 24 (±3 days), then every 12 weeks (±7 days) thereafter; 
hAfter discontinuation, survival status will be obtained (by phone) every 3 months for ≥13 months  
iBlood sample collected for cfDNA predose Cycle 1 Day 1, predose Cycle 2 Day 1, end of cycle 6, predose every 4 cycles, at 
progression (end of study treatment), and 40 days after last dose of study drug administered. Blood samples collected for exosome at 
Harrington Phase 2 SCCHN poster  ASCO 2016; 3-7 June 
 
7 
 
predose cycle 1 Day 1, predose cycle 2 Day 1, and dnd of cycle 6. 
ECG, electrocardiogram; ECOG, Eastern Cooperative Oncology Group; EOI, end of infusion; HAHA, human anti-human antibodies; PK, 
pharmacokinetics. 
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STATISTICAL DESIGN AND ANALYSIS 
 Primary PFS analysis will be conducted when 53 PFS events are observed from approximately 70 
patients with HRG-high status, providing 80% power to detect a 79% increase in median PFS 
(hazard ratio [HR] of 0.56) in HRG-high subjects 
– A stratified log-rank test will be performed to compare the treatment groups for PFS 
and a stratified Cox proportional hazards model will be used to calculate median PFS 
and confidence intervals (CI) 
 Under 2:1 (HRG high vs. low) stratification, approximately 105 subjects (70 HRG-high and 35 
HRG-low) will be randomized in both strata to observe at least 75 PFS events, providing 81% 
power to detect a HR of 0.56 in PFS assuming 1-sided alpha of 0.05 
 Differences in the ORR and OS between 2 arms in both the HRG-high and HRG-low population 
will be presented along with 2-sided 80% and 95% CIs based on the Wilson’s score method with 
continuity correction 
 Serum patritumab, cetuximab, and platinum concentrations and PK parameters will be 
summarised using descriptive statistics 
 
STUDY STATUS 
 Recruitment commenced December, 2015 
 As of April 14, 2016, 6 subjects have enroled among 4 investigational sites in Europe (Figure 4) 
[Authors, these numbers can be updated prior to printing[KF1]] 
 
 
Figure 4. Location of enrolment sites [Authors, figure can be omitted if space is needed]. 
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SUMMARY 
 Data from the phase 1b study demonstrated safety, tolerability, and tumour response of 
patritumab + cetuximab + cisplatin or carboplatin and informed the patritumab dose regimen 
used in the phase 2 study 
 The phase 2 study will evaluate PFS in patients with HRG-high status from subjects treated with 
patritumab or placebo + cetuximab + cisplatin or carboplatin, and further the confirm safety and 
tolerability of the combination of those agents 
 Enrolment is open; additional study information is available on ClinicalTrials.gov (NCT02633800) 
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